Abstract
Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P
| Original language | English (US) |
|---|---|
| Pages (from-to) | 817-825 |
| Number of pages | 9 |
| Journal | Rheumatology |
| Volume | 55 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2016 |
Fingerprint
Keywords
- Antiphospholipid antibodies
- End stage
- Haemodialysis
- Lupus nephritis
- Renal disease
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Rheumatology
- Pharmacology (medical)
Cite this
Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE : A retrospective cohort study. / Broder, Anna R.; Mowrey, Wenzhu Bi; Kim, Mimi; Murakhovskaya, Irina; Billett, Henny H.; Neugarten, Joel; Costenbader, Karen H.; Putterman, Chaim.
In: Rheumatology, Vol. 55, No. 5, 01.05.2016, p. 817-825.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE
T2 - A retrospective cohort study
AU - Broder, Anna R.
AU - Mowrey, Wenzhu Bi
AU - Kim, Mimi
AU - Murakhovskaya, Irina
AU - Billett, Henny H.
AU - Neugarten, Joel
AU - Costenbader, Karen H.
AU - Putterman, Chaim
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P
AB - Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P
KW - Antiphospholipid antibodies
KW - End stage
KW - Haemodialysis
KW - Lupus nephritis
KW - Renal disease
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=84965075882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84965075882&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kev423
DO - 10.1093/rheumatology/kev423
M3 - Article
C2 - 26705328
AN - SCOPUS:84965075882
VL - 55
SP - 817
EP - 825
JO - Rheumatology
JF - Rheumatology
SN - 1462-0324
IS - 5
ER -